Literature DB >> 34907814

Anticancer Activity and Molecular Mechanism of Momordica cochinchinensis Seed Extract in Chronic Myeloid Leukemia Cells.

Zhengdong Ai1,2, Chong Ma1, Ruiming Wan1, Jingyi Yin1, Guiming Li1, Yan Li2, Li Chen1.   

Abstract

Targeting Bcr-Abl is the key to the treatment of chronic myeloid leukemia. Despite great progress in the treatment of patients with chronic CML, advanced CML patients are still unable to obtain effective and safe drugs. Momordica cochinchinensis seed is the dried ripe seed of Momordica cochinchinensis, which is a kind of fruit and consumed for dietary as well as medicinal uses. This study aimed to investigate the anticancer activity of Momordica cochinchinensis seed extract (MCSE) in CML cells. CML cells (KBM5 and KBM5-T315I) were treated with MCSE and analyzed for growth, apoptosis, and signal transduction. Nude mouse xenograft model was used to evaluate the antitumor activity of MCSE In Vivo. MCSE significantly reduced the cell viability of CML cells, triggered G0/G1 phase arrest in KBM5 cells and S phase arrest in KBM5-T315I cells. Concurrently, MCSE caused the activation of caspase-3, -8, -9, PARP and the degradation of Mcl-1, ultimately triggering endogenous and exogenous cell apoptosis. Meanwhile, MCSE downregulated Bcr-Abl levels and its downstream signaling pathways. Additionally, MCSE inhibited the growth of CML cells in nude mouse xenografts. Taken together, this study demonstrated the anticancer mechanism of MCSE, namely blocking Bcr-Abl and downregulating Mcl-1, and finally induced apoptosis of CML cells.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34907814     DOI: 10.1080/01635581.2021.2014904

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.816


  1 in total

1.  Prognostic Value of a Modified Albumin-Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection.

Authors:  Takahiro Shinozuka; Mitsuro Kanda; Dai Shimizu; Chie Tanaka; Yoshikuni Inokawa; Norifumi Hattori; Masamichi Hayashi; Masahiko Koike; Yasuhiro Kodera
Journal:  Ann Surg Oncol       Date:  2022-04-05       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.